One-year RRP and baseline ACPA titres (anti-CCP2, anti-MCV, AhFibA)
| Number of patients with RRP (%) | OR (95% CI) | p Value (χ2) | |
|---|---|---|---|
| Anti-CCP2 | |||
| Negative | 53 (18.0) | 1 | – |
| Low titre (≤3N) | 5 (45.5) | 3.80 (1.11 to 13.10) | 0.0226 |
| High titre (>3N) | 87 (33.5) | 2.30 (1.54 to 3.43) | <0.0001 |
| p Value (OR trend) | 2.90 10−5 | ||
| Anti-MCV | |||
| Negative | 51 (19.0) | 1 | – |
| Low titre (≤3N) | 7 (13.7) | 0.68 (0.29 to 1.59) | NS |
| High titre (>3N) | 87 (35.2) | 2.31 (1.54 to 3.48) | <0.0001 |
| p Value (OR trend) | 2.96 10−5 | ||
| AhFibA | |||
| Negative | 47 (17.3) | 1 | – |
| Low titre (≤3N) | 10 (33.3) | 2.39 (1.04 to 5.49) | 0.0332 |
| High titre (>3N) | 88 (33.3) | 2.39 (1.58 to 3.62) | <0.0001 |
| p Value (OR trend) | 2.08 10−5 | ||
>3N, 3 times the cut-off; ≤3N, ≤3 times the cut-off.
p Value, χ2 test, comparisons of the percentages of patients with negative, low and high titres of antibodies, with negative as the reference.
p Value (OR trend) = test of trend.
ACPA, anticitrullinated peptide antibodies; AhFibA, antihuman citrullinated fibrinogen antibodies; anti-CCP2, anticyclic citrullinated peptides generation 2 antibodies; anti-MCV, antimutated citrullinated vimentine antibodies; RRP, rapid radiographic progression.